Background:Dermatophytoses are the superficial fungal infections of skin, hair, and nail. Butenafine is a benzylamine group of antifungal that inhibits the biosynthesis of ergosterol by blocking squalene epoxidase. Sertaconazole is a newer imidazole antifungal which inhibits the biosynthesis of ergosterol by inhibiting 14-α lanosterol demethylase. The study was done to compare a newer antifungal with a relatively older one.Aim:To compare the efficacy, safety and cost effectiveness of topical 2% sertaconazole cream and 1% butenafine in tinea infections of skin.Materials and Methods:Patients were randomly allocated to two treatment groups. They were advised to apply the drug topically twice a day for one month on the lesions. They were followed up at an interval of 10 days. Clinical score and Global Evaluation Response were assessed at baseline and during each follow up.Results:A total 125 patients were recruited, out of them 111 completed the whole study. Median Sign and Symptom Score of tinea on the baseline was 9 [5,9] that was reduced to 0 [0,4] by 2% sertaconazole while it was 9 [6,9] in the butenafine group on the baseline that was reduced to 0 [0,6] at the end of the treatment. 98% and 90% of the patients got complete clearance of the lesions with butenafine and sertaconazole, respectively. Treatment with butenafine was more cost effective as compared to sertaconazole.Conclusion:1% butenafine is more efficacious, cost effective, and equally safe as compared to 2% sertaconazole in the tinea infections of skin.
Objective: The objective of the study is to study drug utilization in patients with breast carcinoma receiving systemic chemotherapy in government as well as private set-up. Methods: This was a record-based, retrospective-prospective study, analyzing the prescription pattern of drugs used for systemic chemotherapy in patients diagnosed with carcinoma breast at government teaching hospital (GTH) and private trust hospital (PTH) for 1 year in 600 patients. Patient’s demographic, clinical, and therapeutic data were collected from the files and personal interviews and analyzed in Microsoft Excel. Results: Diagnosis of breast carcinoma was highest in age bracket of 40–49 years (32.33% GTH and 32.67% PTH), and the most common presenting symptom was painless lump (76.33% GTH and 83% PTH). In GTH, most frequently prescribed regimen was 4AC → 4T → RT (17.33%). In PTH, most commonly prescribed regimen was 6FEC → RT (19.33%). Highest prescribed drugs were A (32.8%), C (29.12%), and F (20.24%) in GTH and A (32.26%), F (31.68%), and E (16.45%) in PTH. Average number of drugs prescribed per prescription was 12.55 and 11.37; percentage of chemotherapeutic agents prescribed by generic name was 100 and 95.02, and from the WHO essential drug list (2015) was 96.43 and 82.77 in GTH and PTH, respectively (A= Cyclophosphamide, C= Doxorubicin, T=Taxanes [Paclitaxel/Docetaxel], F=5-fluorouracil, E=Epirubicin, RT=Radiotherapy, → followed by, the number indicates chemotherapy cycle). Conclusion: The study results can help in generating local data regarding drug use pattern of the systemic chemotherapeutic agents in breast cancer patients and promote rational drug use.
Aims: To evaluate prescription pattern during second line Antiretroviral Therapy (ART) at tertiary care hospital. Despite a very large number of patient being covered under ART, there are limited data in Indian population regarding second line ART. Therefore, the present study was undertaken. Methods: After consultation with physician of ART plus centre, patient was interviewed and details of the patient's case record was obtained.
Introduction: Despite a very large number of patients being covered under antiretroviral therapy (ART), there are limited data in the Indian population regarding second-line ART. Hence, this study was undertaken to evaluate the efficacy of second-line ART. Materials and Methods: After consultation with the physician of ART Plus Centre, the patient was interviewed, and details of patients' case record were obtained. In our ART Plus Centre, CD4 count has been done at the start and after 6 months of second-line ART which were recorded as effectiveness indicator of second-line ART. Results: Out of seventy patients, 16 (22.86%) had a history of second-line ART from private ART clinics and 54 (77.14%) patients were transferred from other government ART centers. The most common reason to start second-line ART was immunological failure in 27 patients. The mean increase in CD4 count of 106.09 cells/mm 3 was observed after 6 months of second-line ART in 63 patients. The mean increase in CD4 count (57.16%) after 6 months was statistically significant ( P < 0.05) with tenofovir + lamivudine + atazanavir/ritonavir regimen in forty patients. Conclusions: Irrational practice by private hospitals limits treatment options, with increasing the chances of drug resistance. On the other hand, the National AIDS Control Organization-sponsored second-line ART was found to be effective as 84.12% of patients had improvement in their mean CD4 count.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.